Skip to main content

Table 2 Factors associated with the persistence of imatinib initial therapy

From: Trends in the treatment changes and medication persistence of chronic myeloid leukemia in Taiwan from 1997 to 2007: a longitudinal population database analysis

Characteristics Non-persistenta Persistent χ2 OR for being persistent (95% CI) p value
  (n = 479) (n = 303) (p-value)   
Age at diagnosis, y, n (%)    2.08 (0.15)   
   ≥40, 308 (64.3) 210 (69.3)   1.4 (0.9 to 2.1) 0.15
   <40 171 (35.7) 93 (30.7)   1 (referent)  
Gender, n (%)    0.44 (0.51)   
   Male 281 (58.7) 185 (61.1)   1.4 (0.9 to 2.1) 0.10
   Female 198 (41.3) 118 (38.9)   1 (referent)  
Charlson comorbidity score, n (%)    1.39 (0.24)   
   >0 215 (44.9) 123 (40.6)   0.8 (0.5 to 1.1) 0.16
   =0 264 (55.1) 180 (59.4)   1 (referent)  
CML diagnosis, n (%)    11.97(<0.001)   
   ≥2004 260 (54.3) 126 (41.6)   4.1 (2.2 to 7.9) <.0001
   <2004 219 (45.7) 177 (48.4)   1 (referent)  
CML severity, n (%)    7.60 (0.06)   
   Unknown 28 (5.9) 24 (7.9)   0.6 (0.2 to 1.6) 0.20
   Low 2 (0.4) 2 (0.7)   1.4 (0.1 to 19.0) 0.77
   Moderate 378 (78.9) 251 (82.8)   1.5 (0.8 to 3.0) 0.30
   High 71 (14.8) 26 (8.6)   1 (referent)  
Prior treatment, n (%)
   Hydroxyurea 342 (71.4) 225 (74.3) 0.76 (0.38) 1.8 (1.1 to 2.8) 0.02
   Busulfan 8 (1.7) 9 (3.0) 1.48 (0.22) 0.5 (0.1 to 2.0) 0.34
   IFNα/Ara-C 72 (15.0) 75 (24.8) 11.49(<0.001) 1.9 (1.1 to 3.3) 0.02
Mean time to imatinib initiation, month (SD) 14.1 (19.6) 15.4 (19.4) 0.89 (0.37)d 1.0 (0.99 to 1.02) 0.42
Mean starting daily dose, mg/day (SD)b 362 (141) 375 (108) 1.35 (0.18) d 1.1 (0.97 to 1.34) 0.11
Mean treatment duration, months (SD) 16.5 (16.8) 41.2 (14.2) 21.94 (<.0001) d 1.1 (1.09 to 1.13) <.0001
HSCT post-index date, n (%) 35 (7.3) 2 (0.7) 18.19(<.0001) 0.1 (0.02 to 0.5) 0.01
  1. a. Patients were considered persistent if they were taking imatinib without interruption (exceeding a 60-day permissible gap) for at least 18 months since the start of therapy.
  2. b. Excluding patients with a single imatinib claim (n = 19).
  3. c. OR = odds ratio, each OR of the variable was adjusted by the other factors in the logistic regression model.
  4. Abbreviations: CML, chronic myeloid leukemia; IFNα, interferon-α; Ara-C, cytarabine; HSCT, hematopoietic stem cell transplantation.
  5. d. t test for numerical outcomes.